Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors

  • Financing led by Brandon Capital, Forbion and Atlas Venture
  • Aims to advance its lead ADC compound targeting a novel cancer antigen
  • Serial biotech entrepreneur Bertrand Damour appointed as Chief Executive Officer
  • Industry veteran Leigh Zawel appointed as Chief Scientific Officer
  • Proprietary payload platform for development of novel ADCs

London UK, 28 September 2022 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, launched today following the closing of a $68 million Series A financing in March 2022. The investment will enable Pheon to advance its lead ADC program to clinical proof-of-concept and establish a pipeline of novel ADCs. The financing was led by Brandon Capital, Forbion and Atlas Venture, with participation from seed investor Research Corporation Technologies (RCT).

Read more